From the Guidelines
Vyepti (Eptinezumab) is a preventive medication for migraine, specifically a calcitonin gene-related peptide (CGRP) antagonist.
Key Points
- Administration: Vyepti (Eptinezumab) is administered intravenously, with dosages of 100 or 300 mg quarterly 1.
- Indications: It is used for the prevention of episodic and chronic migraine.
- Mechanism of Action: As a CGRP antagonist, it works by blocking the CGRP receptor, which is involved in the pathophysiology of migraine.
- Recommendation: The 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline for the management of headache suggests Vyepti (Eptinezumab) for the prevention of episodic or chronic migraine, with a "weak for" recommendation 1.
- Contraindications and Precautions: While specific contraindications for Vyepti (Eptinezumab) are not extensively detailed in the provided evidence, it is essential to consider the general precautions and potential side effects associated with CGRP antagonists, such as hypersensitivity reactions and potential impacts on cardiovascular health 1.
Given the information and the context of real-life clinical medicine, Vyepti (Eptinezumab) is considered a viable option for patients with episodic or chronic migraine who have not responded to other preventive treatments or have specific needs that align with the mechanism of action and administration of this medication.
From the FDA Drug Label
VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.
VYEPTI (eptinezumab-jjmr) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to brownish-yellow solution, for intravenous infusion.
Eptinezumab-jjmr is a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand.
Vyepti (Eptinezumab) is a prescription medicine used for the preventive treatment of migraine in adults. It is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. 2 2
From the Research
Definition and Mechanism of Action
- Vyepti, also known as eptinezumab, is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) developed by Lundbeck Seattle BioPharmaceuticals, Inc. 3
- It works by binding to CGRP and blocking its binding to the receptor, which is believed to play a major role in the pathophysiology of migraine 4
Administration and Dosage
- Eptinezumab is administered by an intravenous infusion at a 100 mg dose every 3 months 3
- It is also available in a 300 mg dose, which has shown to be effective in reducing monthly migraine days 5
Efficacy and Safety
- Studies have shown that eptinezumab is an effective preventative medication in migraine, starting to show its effect from day 1 of its administration and maintaining a consistent level of efficacy through a year of treatment 3, 5
- It has been found to be effective in reducing time to headache pain freedom during acute migraine attacks and in reducing monthly migraine days in both episodic and chronic migraine sufferers 3, 5
- Eptinezumab is considered to be relatively safe, with treatment-related adverse events occurring at a low frequency, and is well-tolerated in patients with comorbidities such as obesity and type 1 diabetes 3
- The most common adverse events observed were nasopharyngitis, upper respiratory tract infections (URTIs), and sinusitis, which were usually mild 3
Clinical Applications
- Eptinezumab has been approved in the USA for the preventive treatment of migraine in adults 4
- It has been shown to be beneficial for people with chronic migraine and medication-overuse headache, reducing migraine days, severity of migraine attacks, and use of acute medication 6
- Eptinezumab is part of a new generation of CGRP-targeting medications and has shown significant evidence to support its use for the prevention of migraines 7